Background: Topical Brimonidine is approved by FDA for the treatment of rosacea-associated erythema. It has antiinflammatory action, in additional to its vasoconstrictive activity, it preventes leucocyte recruitment via inhibition of transendothelial cells migration. Briominidine has been studied for many indications rather than rosacea with positive results. Objective: Review of the literature on the effectiveness of topical brimonidine in the treatment of various dermatological diseases. Methods: A comprehensive search was conducted in PubMed, Google Scholar, and Science Direct for information on Topical Brimonidine dermatological diseases. However, only the most current or comprehensive study from May 2011 to November 2022 was considered. The authors also assessed references from pertinent literature. Documents in languages other than English have been disregarded since there are not enough resources for translation. Unpublished manuscripts, oral presentations, conference abstracts, and dissertations were examples of papers that were not considered to be serious scientific research. Results: Mild, temporary skin-related adverse effects have been reported with 0.33 percent brimonidine topical gel. Maximum erythema reduction may occur 3-6 hours after application, while some patients report seeing results as early as 30 minutes. Conclusion: Combination therapy with brimonidine gel and other treatments for face papules and pustules is safe and does not enhance the risk of adverse outcomes.

Background: Insulin exerts metabolic and growth-stimulating actions both through its own receptors and the receptors of its homologous factors (IGFs), although with different degrees of affinity. The A receptor of insulin acts more intensely on the cell membrane, with a metabolic response, whereas the B receptor is quickly internalized, stimulates cell growth, can be directed to the treatment of wounds difficult to heal. The intraregional use of insulin ensures its absorption, greater stability, longer activity period and absence of contact with necrotic or enzymatic materials capable of preventing or changes its activity in topical use. Objective: in this article, we aimed to study the role of insulin in dermatology and skin diseases. Methods: We searched online databases (PubMed, Embase, and the Cochrane Library), to include studies that discuss the role of insulin in skin diseases, all types of studies are included. Conclusion: Insulin therapy has been shown to be effective and without adverse effects. Different intervals between applications did not change the obtained results. The availability of insulin and the safety of its use indicate the authors' method as an advantageous therapeutic option in the recovery of tissues. The availability, low cost and wide knowledge available on this substance justify its indication as a therapeutic method for, are difficult to heal wounds.

No abstract